Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial
The Lancet Neurology（2023）
摘要
Patient-Centered Outcomes Research Institute and the National Multiple Sclerosis Society.
更多查看译文
关键词
multiple sclerosis,new disease activity,therapies,disease-modifying,single-blind,non-inferiority
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要